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Abstract
Objective To assess whether interspinous process device implantation
is more effective in the short term than conventional surgical
decompression for patients with intermittent neurogenic claudication
due to lumbar spinal stenosis.
Design Randomized controlled trial.
Setting Five neurosurgical centers (including one academic and four
secondary level care centers) in the Netherlands.
Participants 203 participants were referred to the Leiden-The Hague
Spine Prognostic Study Group between October 2008 and September
2011; 159 participants with intermittent neurogenic claudication due to
lumbar spinal stenosis at one or two levels with an indication for surgery
were randomized.
Interventions 80 participants received an interspinous process device
and 79 participants underwent spinal bony decompression.
Main outcome measures The primary outcome at short term (eight
weeks) and long term (one year) follow-up was the Zurich Claudication
Questionnaire score. Repeated measurements were made to compare
outcomes over time.
Results At eight weeks, the success rate according to the Zurich
Claudication Questionnaire for the interspinous process device group
(63%, 95% confidence interval 51% to 73%) was not superior to that for
standard bony decompression (72%, 60% to 81%). No differences in
disability (Zurich Claudication Questionnaire; P=0.44) or other outcomes
were observed between groups during the first year. The repeat surgery
rate in the interspinous implant group was substantially higher (n=21;
29%) than that in the conventional group (n=6; 8%) in the early
post-surgical period (P<0.001).
Conclusions This double blinded study could not confirm the
hypothesized short term advantage of interspinous process device over
conventional “simple” decompression and even showed a fairly high
reoperation rate after interspinous process device implantation.
Trial registration Dutch Trial Register NTR1307.
Introduction
Recent developments in spinal surgery implants promise less
invasive procedures with superior effectiveness to conventional
surgery.1 Particularly in (older) patients with spinal stenosis due
to arthrosis of the facet joints, implantation of an interspinous
process device is regularly offered. However, the growing
incidence of low back surgery with additional implants for
degenerative spine disease has raised questions from the
scientific community.2 3 Furthermore, the economic burden of
management of lumbar spine disorders (lumbar spinal disorder
and lumbar disc disease combined) was already worrisome in
the 1990s, when they ranked fifth on the basis of cost of hospital
care.4 The increasing use of implants, combined with a growing
older population, leads to societal concerns as the cost of the
management of spinal stenosis is escalating.5 6
Lumbar degenerative spinal stenosis is caused by arthrosis of
the facet joints and development stenosis, which can result in
lumbar nerve root compression.7 As in other acquired diseases,
intermittent neurogenic claudication is usually seen in older
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people.8 Severe stenosis is common in older people’s spines:
30.4% of the Japanese population had a severe stenosis (average
age 67.3 (range 40-93) years).9Why only 17.5% of these patients
have typical symptoms is not yet known. Most of these patients
complain of a complex of symptoms, described as leg pain
(frequently in both legs), which is exacerbated by walking,
prolonged standing, or lumbar extension.7-11 Classically, the
cramp, tightness, pain, or discomfort in the legs will diminish
after a short period of sitting or bending forward.8 Apart from
the leg pain, associated low back painmay occur.12The optimum
treatment of lumbar spinal stenosis is generally considered to
be surgical intervention, as two randomized clinical trials
comparing conservative treatment with conventional bony
decompression resulted in treatment effects in favor of
surgery.13 14 The treatment outcome falls short of surgeons’
expectations, as surgical decompression yields a modest
outcome, being favorable in only 65% of patients.13-17 This
slightly disappointing success rate is said to be due to the
destructive nature of bony decompressive surgery of the spinal
column.18 19 Instability of the lumbar spine follows laminectomy,
requiring subsequent instrumental spondylodesis.20 21 Spinal
surgeons and the medical device industry are therefore looking
for a less detrimental alternative in the surgical care for the older
population.
Minimally invasive surgery has gained popularity in recent
years, resulting in the development of various interspinous
process devices.22 The interspinous process device was
developed to stabilize and increase the interspinous distance
with indirect decompression of the dural sac and nerve roots.23-33
Treatment of neurogenic claudication with has been shown to
be superior to conservative care.34-36 The Coflex implant
(Paradigm Spine, USA) was developed as a second generation
interspinous process device to give indirect decompression with
the possibility of stabilizing the lumbar spine after bony
decompression. Although some medical societies in Western
countries believe in additional pedicle screw fixation of the
lumbar spine, the scientific gold standard of surgical treatment
of lumbar spinal stenosis is bony decompression.37 38 All new
surgical techniques to treat lumbar spinal stenosis should be
compared with this technique.13-39 Although society might be
subjected to media driven medicine and early adoption of
surgical implants, the spinal scientific community believes that
well designed comparative studies should be conducted before
a new implant can replace the gold standard. Interspinous
process devices have been suggested to have better short term
(eight weeks) recovery than and similar long term (cost)
effectiveness to bony decompression.23-41 The purpose of this
study was to assess whether interspinous process device
implantation is more effective in the short term than
conventional surgical decompression for patients with
intermittent neurogenic claudication due to lumbar spinal
stenosis.
Methods
We did a prospective, randomized, double blind, multicenter
trial among patients with intermittent neurogenic claudication
due to lumbar spinal stenosis after failed conservative treatment
(Foraminal Enlargement Lumbar Interspinosus distraXion:
FELIX trial). We compared minimally invasive treatment with
interspinous process devices against usual care (conventional
bony decompression). The design and study protocol have been
published previously.42
Eligibility and randomization
Patients aged between 40 and 85 years with at least three months
of intermittent neurogenic claudication due to single or two
level degenerative lumbar canal stenosis and an indication for
surgery were eligible. All patients were diagnosed as having
intermittent neurogenic claudication by a neurologist in one of
the participating hospitals. If magnetic resonance imaging
showed a lumbar spinal canal stenosis, the consulting
neurosurgeon could include patients as surgical candidates for
the study. At the time of enrollment, an independent research
nurse verified the persistence of the symptoms. We excluded
patients with a cauda equina syndrome, a herniated disc needing
discectomy, history of lumbar surgery, or significant scoliosis
(Cobb angle >25°) or other spinal deformities.
We used a randomized design with variable block sizes, with
allocations stratified according to center. Allocations were stored
in prepared opaque, coded, and sealed envelopes. The key was
accessible only to the ProMISe data management system of the
Department of Medical Statistics and BioInformatics of the
Leiden University Medical Center. All patients gave informed
consent. After induction of anesthesia, the prepared envelope
was opened and the patient allocated to one of the treatment
arms. Patients, nurses on the hospital wards, and research nurses
remained blind to the allocated treatment during the follow-up
period of one year. The surgical report was kept separately from
the patient’s regular clinical forms and was available to the
neurosurgeon only in case of complications or reoperations.
Interventions
Patients allocated to the experimental group were operated on
under general anesthesia in the knee-elbow position; no bony
decompression was done, and an interspinous process device
was implanted by a posterior midline approach using
radiographic data for localization of the appropriate level.
Patients in the standard bony decompression group had surgery
in the same knee-elbow position done using a similar incision
length to the interspinous process device group to keep all
caregivers blind to the allocated treatment. A partial resection
of the adjacent laminas was executed, followed by a flavectomy
with bilateral opening of the lateral recess. If judged necessary,
a medial facetectomywas done. Patients in both groups received
the same standard postoperative care. Patients and the research
nurses who were following them were asked after every visit if
they were still blind to the allocated treatment.42
Outcomes
The primary outcomemeasure was a disorder specific functional
score, obtained by the Zurich Claudication Questionnaire.43-45
The primary outcome score was assessed at baseline and at 2,
4, 8, 12, 26, and 52 weeks after surgery. The questionnaire
consists of three domains (symptom severity, physical function,
and patients’ satisfaction), in which respectively seven, five,
and six questions are answered on a five point (symptom
severity) or a four point (physical function and patients’
satisfaction) scale. The subscale scores were the averages of the
points obtained for every question of the subscale, with a
maximum score of 5 for symptom severity and 4 for physical
function and patients’ satisfaction. The score increases with
increasing disability. Blinded research nurses obtained the
average subscale scores at every follow-up visit.42We considered
the overall Zurich Claudication Questionnaire score to represent
a “successful recovery” when at least two domain subscales
were judged as “success.”46 We defined “success” on the
symptom severity scale and on the physical function scale as a
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6415 doi: 10.1136/bmj.f6415 (Published 14 November 2013) Page 2 of 12
RESEARCH
decrease of at least 0.5 points; a score of less than 2.5 on the
patients’ satisfaction subscale represented “success.”44 45
Secondary outcome measures were the modified Roland
Disability Questionnaire for sciatica (scores range from 0 to 23,
with higher scores indicating worse functional status),47-55 a 100
mm visual analogue scale for back and leg pain (with 0
representing no pain and 100 the worst pain ever experienced),56
the Medical Outcomes Study 36 item Short Form Generated
Health Survey (SF-36) scale (based on eight scaled scores, which
are the weighted sums in their sections),57 58 the McGill Pain
Questionnaire (with 0 representing minimum pain score and 78
maximum pain score),59 60 and a seven point Likert-type self
rating scale of global perceived recovery as assessed by the
question of whether the patient had experienced recovery
(dichotomized into 1-2 for recovery and 3-7 for no recovery).61
Furthermore, patients underwent a shuttle walking test with a
predefined maximum distance and timeframe (1200 m or 15
min).62 Patients were scored as “success” when they walked
1200 m within 15 minutes or showed an increase of more than
80m compared with their baseline walking distance.42-64 Finally,
we used a Hospital Anxiety and Depression Scale consisting of
a seven item depression scale and a seven item anxiety scale (4
point scale from 0 to 3).65 The seven items of the depression
scale are related (if more than 8 points) to depression, and the
seven items of the anxiety scale are related (if more than 8
points) to generalized anxiety disorder.66 Most studies report a
cut-off point at 8 points. We assessed secondary outcome scores
at baseline and at two (only visual analogue scale back and leg
pain), eight 12, 26, and 52 weeks. The Hospital Anxiety and
Depression Scale anxiety and depression scores were obtained
at baseline and after 52 weeks.
Sample size
The aim of this study was to assess whether the experimental
surgical technique with an interspinous process device would
be superior to conventional surgery for patients with intermittent
neurogenic claudication due to lumbar spinal stenosis on short
term outcome scales. Based on our main outcome score (Zurich
Claudication Questionnaire) and an assumedminimal clinically
important change of 20% difference in the overall success rate
between the two groups at eight weeks and 10% loss to
follow-up, we calculated that a sample size of 80 patients in
each treatment group would be required to provide a statistical
power of 0.80 and a two sided α of 0.05.43-46We determined this
20% success rate on the basis of the assumption that superiority
would be convincing enough to change the surgical guidelines.
Researchers had access to the data only after the full follow-up
period of one year.
Statistical analysis
We compared groups on the basis of an intention to treat
analysis. We analyzed differences between groups at all the
follow-up (2, 4, 8, 12, 26, and 52 weeks) time points with
repeated measurement analysis. To account for the correlation
between repeated measurements of the same person, we used
generalized estimating equations. We present the difference
between the results for the two groups as an odds ratio for binary
outcome variables and as mean differences for continuous
outcome variables.42 To investigate potential bias due to loss to
follow-up, we did a sensitivity analysis for the primary outcome
by assigning a poor outcome to all missing cases.
At randomization, the administrative center stratified the study
for the purpose of analyzing possible heterogeneity among
centers and attempting a clinical interpretation of such
heterogeneity.We tested heterogeneity between centers by using
center as a covariate in the mixed model. We combined those
centers that were referring patients to the same hospital and the
same surgeon for treatment. Hence, for the analysis of
heterogeneity, a center means the actual location where the
treatment (according to random allocation) took place. We used
the ProMISe data management system of the Department of
Medical Statistics and BioInformatics of the Leiden University
Medical Center Data for collection of data and checking for
quality. We used IBM SPSS software, version 20.0, for all
statistical analysis.
Results
Between October 2008 and September 2011, 203 patients with
intermittent neurogenic claudication due to spinal stenosis were
referred to the Leiden-TheHague Spine Prognostic StudyGroup.
For all patients, the including neurosurgeon confirmed a single
or two level, magnetic resonance imaging confirmed,
degenerative stenosis and intermittent neurogenic claudication
according to the referring neurologists. One hundred and sixty
two patients gave informed consent and were enrolled in the
FELIX trial (fig 1⇓). One patient died while waiting for the
operation. Two patients were found to have a severe
spondylolysis of the L5-S1 segment at the final preoperative
check-up and were excluded from the study, because this could
cause a detrimental effect in the implant group. The remaining
patients were randomly assigned to interspinous process device
or decompression, and 159 patients received the allocated
treatment. All patients had had intermittent neurogenic
claudication for an average period of 23 (intermittent neurogenic
claudication group) and 22 (decompression group) months. No
significant differences were noted in baseline characteristics
between patients in the two treatment arms (table 1⇓). Seven
patients were lost to follow-up in the interspinous process device
group and one patient in the bony decompression group.
Successful recovery according to the Zurich Claudication
Questionnaire at short term follow-up (eight weeks) was
achieved by 63% of the patients in the interspinous process
device group compared with 72% in the bony decompression
group (odds ratio 0.73; P=0.44. Long term (one year) successful
recovery according to the Zurich Claudication Questionnaire
was similar in the two groups, resulting in 66% good results in
the interspinous process device group and 69% in the bony
decompression group (odds ratio 0.90; P= 0.77). Overall, the
Zurich Claudication Questionnaire analysis showed no
differences between the two treatment arms (table 2⇓; fig 2⇓).
Modified Roland Disability Questionnaire values at eight weeks
recovered by a mean score of 7.5 for patients treated with
interspinous process device and by a mean score of 6.5 for those
treated with bony decompression (P=0.28). Generalized
estimating equations analysis showed no differences between
the two treatment arms (table 2⇓; fig 2⇓). Analysis of all other
subscales—visual analogue scale back pain (P=0.09), visual
analogue scale leg pain (P=0.54), McGill Pain Questionnaire
(P=0.70), and Likert scale for perceived recovery
(P=0.37)—showed no differences during the complete follow-up
(table 2⇓; fig 2⇓).We found no statistically significant difference
in walking distance in the shuttle walking test at eight weeks
(odds ratio 0.75; P=0.33) and 52 weeks (1.25; P=0.54) between
the two treatment groups. Generalized estimating equations
analysis on visual analogue scale back pain and leg pain, SF-36,
McGill Pain Questionnaire, Likert score for perceived recovery,
shuttle walking test, and Hospital Anxiety and Depression Scale
scores also showed no differences (tables 2⇓ and 3⇓). We did
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not adjust primary outcome scores for Hospital Anxiety and
Depression Scale depression because of the small percentage
of participants with a score of 8 or more (indicating depression).
Surgery time (24 min) was shorter in the interspinous process
device group than for bony decompression (43 min) (P<0.001).
Blood loss was less in the interspinous process device group
(10-50mL) than in the bony decompression group (50-100mL)
(P<0.001). Five direct (that is, during the initial hospital stay)
postoperative complications occurred in the interspinous process
device: one patient with short term (48 hours) unexplained visual
disturbance, one patient with self limiting pseudoradicular pain
in the other leg, and three patients with interspinous process
fractures during interspinous process device placement (table
3⇓). Direct postoperative complications occurred in six patients
in the bony decompression group: two patients with direct
epidural hematoma needing reoperation and four patients with
dural tears without further consequences. Late reoperation due
to absence of recovery was indicated and performed in 21/73
(29%) cases in the interspinous process device group compared
with 6/72 (8%) in the bony decompression group (P<0.001).
Of patients who initially received an interspinous process device
and were reoperated (explantation of the device and subsequent
bony decompression), 48% scored successful recovery on the
Zurich Claudication Questionnaire; of patients in the bony
decompression group who were reoperated, 50% scored
successful recovery. The Zurich Claudication Questionnaire
outcome of the patients reoperated after interspinous process
device placement did not differ significantly from that of the
other patients (P=0.08). Average hospital stay was similar in
both groups: 1.83 days for the interspinous process device group
and 1.89 days for the bony decompression group (P=0.753).
Patients were successfully blinded to the treatment chosen in
67% of the IPD group and 86% of the standard decompression
group.
We did a sensitivity analysis to assess the effect of the missing
values for our primary outcome. Firstly, we replaced all missing
values with unfavorable outcomes. This did not affect our results
in any substantial way. Next, we replaced all missing values
with favorable outcomes. Again, we saw no substantial changes
to our results. The results for the primary outcome were
therefore not sensitive to loss to follow-up.
Thirty seven patients were operated on at two levels (tables 1⇓
and 3⇓). The subgroup of patients with lumbar spinal stenosis
operated on at two levels with an interspinous process device
(21 patients) had a similar outcome on the Zurich Claudication
Questionnaire scale at eight weeks (odds ratio 2.5; P=0.06) and
at one year (0.83; P=0.83) to those allocated to the bony
decompression group (18 patients). Generalized estimating
equations analysis showed no difference in Zurich Claudication
Questionnaire results between one and two levels of surgery
(P=0.44). However, the reoperation rate of 38% (eight patients)
in the interspinous process device group at two levels was higher
than the reoperation rate in the bony decompression group of
6% (one patient) (P<0.05).
We found no clinically significant heterogeneity in the outcomes
between the five centers (supplementary appendix). The small
difference supports the contention that the sample of hospitals
is a good representation of the Dutch healthcare system.
Discussion
Implantation of an interspinous process device as definite
treatment for lumbar spinal stenosis did not show the
hypothesized short term superior effect over standard bony
decompressive surgery. The one year follow-up results of both
surgical procedures did not differ, although the reoperation rate
for the interspinous process device was significantly higher than
that for conventional bony decompression. Another study started
in 2007 was terminated when an interim analysis showed a
fourfold higher reoperation rate in the interspinous process
device group.67 The shorter operation time was the only
beneficial parameter for patients in the interspinous process
device group compared with the bony decompression group,
but this did not result in a shorter hospital stay. Furthermore,
patients operated on at two levels had an even higher reoperation
rate compared with bony decompression. The absence of short
term added value of the interspinous process device and the
much higher reoperation rate in this study do not allow this new
procedure to replace the golden standard of simple bony
decompression as treatment for lumbar spinal stenosis.
Strengths and limitations of study
One of the strengths of this study is that this is the first and only
blinded randomized study on this subject. Furthermore, by
anomyzation during data analysis, we excluded bias as much
as possible. However, the study has also features that may limit
the generalizability of its findings. Firstly, selection bias could
have been introduced through the opinion of the including
neurosurgeon that patients with severe spinal stenosis on
magnetic resonance imaging should not be offered an
interspinous process device and were thus not included in the
FELIX trial. However, clinical features of the patients included
in this study showed baseline values (mean visual analogue
scale (leg and/or back) of 60 mm at baseline) comparable to
those of other large trials.13 14 Trials in general tend to include
standard patients, but, as mentioned earlier, not all patients with
stenosis have clinical complaints, which could lead to potential
bias that may limit the generalizability. The number of
reoperations in the interspinous process device treatment arm
is very worrisome, especially because reoperations do not reach
the success rate of primary surgeries; use of interspinous process
devices might even prevent recovery in 20% of patients. Lastly,
shuttle walking tests are believed to be the most objective
parameter to classify the disease specific complaints of lumbar
spinal stenosis. As in many other studies, however, using this
test for an older population is often difficult.13 Further research
should focus on finding a new objective parameter to evaluate
the increasingly older population with lumbar spinal stenosis.
Comparison with other studies
Others researchers have tested the interspinous process device
as an alternative for posterior and intercorporal fusion in patients
with lumbar spinal stenosis.68 69 In Dutch practice, instrumental
spondylodesis is not a standard adjuvant in spinal stenosis
surgery, and nor is it standard in the modern literature. 35-42
Nevertheless, two studies compared a wide laminectomy
combined with interspinous process device placement against
treatment with wide laminectomy combined with posterior and
intercorporal fusion.68 69 Both studies concluded that adjuvant
interspinous process device treatment is as effective as lumbar
360° instrumentation in resolving neurogenic claudication. In
addition, a non-randomized study had already shown that
patients with intermittent neurogenic claudication treated with
bony decompression alone had the same long term satisfactory
outcome as did patients treated with bony decompression and
adjuvant interspinous process device placement.70 71 Furthermore,
a recent smaller non-blinded study reported similar results to
those presented here. The clinical outcome of patients treated
with an interspinous process device was not superior to that in
patients treated with bony decompression. As in our study,
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patients had a higher rate (26% v 6%) of reoperation in the
interspinous process device group.72 All studies, including our
trial, found no differences between groups with regard to
postoperative visual analogue scale leg and back pain.68 69
The results of this study and previous studies lead to the overall
conclusion that intermittent neurogenic claudication treated
with decompression alone results in a comparable outcome
compared with treatment with interspinous process device alone,
interspinous process device combinedwith bony decompression,
and 360° instrumented spondylodesis. As instrumented surgery
requires more from society and patients, the gold standard for
intermittent neurogenic claudication treatment remains the
classic bony decompression.
Conclusions
The hypothesized short term superior effect of treatment with
interspinous process device over simple standard surgery was
not confirmed by this double blind study. In contrast, treatment
with interspinous process devices resulted in a higher reoperation
rate and thus prevented a better recovery owing to the lower
recovery rate after a second operation. As a spinal research
group, we would not recommend the interspinous process
device, considering the higher reoperation rate without a short
term advantage and most likely with higher costs (interspinous
process devices cost at least €2000 (£1704; $2756)). We doubt
if reimbursement of interspinous process devices by society is
appropriate. Furthermore, this study shows that future research
in spine surgery should be very critical in the evaluation of a
so called favorable outcome and weigh this against the
disadvantages in robust double blind randomized trials.
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Tables
Table 1| Characteristics of patients at baseline. Values are numbers (percentages) unless stated otherwise
Decompression group (n=79)IPD group (n=80)Characteristic
64 (47-83)66 (45-83)Median (range) age (years)
37 (47)49 (61)Male sex
22 (1-204)12 (2-120)Median (range) duration of intermittent neurogenic claudication
(months)
28 (20-37)27 (20-48)Median (range) body mass index*
1-3 years1-3 yearsDuration of back pain (categorized)
36 (46)39 (49)IPD patient’s preferred treatment†
3 (4)0 (0)Bony decompression patient’s preferred treatment†
40 (50)41 (51)No preference for specific treatment†
56 (71)54 (67)Mild paresis or sensory loss
Localization of stenosis:
3 (4)2 (3)L2-L3
22 (28)25 (31)L3-L4
54 (68)53 (66)L4-L5
16 (20)21 (26)Operated at two levels:
3 (4)2 (3)L2-L3-L4
0 (0)1 (1)L2-L3 and L4-L5
13 (16)17 (21)L3-L4-L5
Zurich Claudication Questionnaire‡:
3.2 (0.5)3.1 (0.5)Mean (SD) subscale symptom severity 0-5 scale‡
2.6 (0.5)2.6 (0.5)Mean (SD) subscale physical function 0-4 scale‡
14.4 (4.5)13.0 (5.2)Mean (SD) Roland Disability Questionnaire 23 points
58 (24)52 (24)Mean (SD) VAS leg pain (mm)§
49 (25)60 (44)Mean (SD) VAS back pain (mm)§
140 (10-1220) (n=70)180 (20-1260) (n=70)Median (range) SWT (m)¶
13 (16)8 (10)Completed SWT¶
IPD=interspinous process device; SWT=shuttle walking distance; VAS=visual analogue scale.
*Weight in kilograms divided by square of height in meters.
†Patients were asked if they had any treatment preference (no preference, IPD, or bony decompression).
‡Disease specific outcome score; at baseline, score was reported in two subdomains—symptom severity (range 0-5) and physical function (range 0-4).
§Intensity of pain was measured by horizontal 100 mm VAS, with 0 representing no pain and 100 worst pain ever.
¶Obtained before operation; patients were asked to walk until they got symptoms; test was scored “complete” when patients walked 1200 m in 15 min without
stopping.
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Table 2| Primary and secondary outcomes*
52 weeks (n=144)26 weeks (n=141)8 weeks (n=142)2 weeks (n=129)
Baseline
(n=159)
Variable BDIPDBDIPDBDIPDBDIPDBDIPD
OR (P
value)
OR (P
value)
OR (P
value)
OR (P
value)
Primary
outcome
0.90
(0.77)
69 (57
to 78)
66 (54
to 74)
1.20
(0.64)
63 (50
to 74)
64 (53
to 74)
0.73
(0.44)
72 (60
to 81)
63 (51
to 73)
1.64
(0.18)
57 (45
to 69)
67 (55
to 77)
NANA% (95% CI)
success
ZCQ
MDMDMDMDSecondary
outcomes
1.2
(0.28)†
8.1 (6.6
to 9.7)
6.9 (5.4
to 8.5)
NANANA1.06.5 (5.3
to 7.8)
7.5 (6.1
to 9.0)
0.110.6
(9.3 to
12.0)
10.4
(9.2 to
11.8)
14.4
(13.3 to
15.5)
13.0
(11.7 to
14.2)
Mean (95%
CI) MRDQ
(23 points)
score
8
(0.09)†
31 (24
to 37)
23 (17
to 29)
NANANA123 (17
to 28)
24 (19
to 30)
133 (28
to39)
32 (27
to38)
49 (44
to56)
60 (37
to 83)
Mean (95%
CI) VAS
back pain
(0-100 mm)
3
(0.54)†
26 (20
to 33)
23 (17
to 30)
NANANA422 (18
to 27)
26 (20
to 32)
326 (20
to 32)
23 (18
to 28)
58 (52
to 64)
52 (47
to 59)
Mean (95%
CI) VAS leg
pain (0-100
mm)
OR (P
value)
OR (P
value)
1.37
(0.37)
49 (38
to 60)
56 (45
to 67)
NANANA0.94
(0.85)
53 (41
to 64)
51 (40
to 63)
NANANANANAMean (95%
CI) Likert %
perceived
success‡
BD=bony decompression; IPD=interspinous process device; MD=mean difference; MRDQ=modified Roland Disability Questionnaire; NA=test not administered;
OR=odds ratio; VAS=visual analogue scale; ZCQ=Zurich Claudication Questionnaire.
*Outcomes were analyzed with generalized estimating equations (GEE). Outcome was reported as odds ratio for better success rate when treated with IPD versus
bony decompression and overall P value (based on GEE) of interaction between two groups based on continuous outcome scales with mean differences (MRDQ
and VAS).
†Overall score in continuous outcome scales were not significant (MRDQ and VAS).
‡Likert global perceived recovery defined by 7 point scale from “worse” to “complete” recovery; score was dichotomized between good recovery (1-2) and bad
recovery (3-7).
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Table 3| Secondary outcomes at 8 and 52 weeks*
Odds ratio† (P value)DecompressionIPDOutcome
% success (95% CI) on shuttle walking test:
0.75 (0.33)59 (0.47 to 0.88) (n=72)57 (0.45 to 0.68) (n=73)8 weeks (increase of 80 m or complete)
1.25 (0.54)51 (0.40 to 0.62) (n=70)57 (0.43 to 0.69) (n=66)52 weeks (increase of 80 m or complete)
Mean (95% CI) SF-36 score:
(0.40)‡63 (58 to 68)66 (61 to 71)Bodily pain 8 weeks
62 (57 to 68)66 (60 to 72)Bodily pain 52 weeks
(0.72)‡67 (62 to 72)64 (59 to 70)Physical functioning 8 weeks
62 (56 to 68)63 (58 to 69)Physical functioning 52 weeks
(0.95)‡76 (70 to 82)74 (69 to 80)Social functioning 8 weeks
77 (72 to 82)77 (70 to 83)Social functioning 52 weeks
(0.96)‡42 (33 to 51)44 (34 to 54)Physical role 8 weeks
55 (46 to 65)55 (45 to 65)Physical role 52 weeks
(0.46)‡80 (72 to 88)74 (65 to 83)Emotional role 8 weeks
79 (71 to 87)74 (65 to 83)Emotional role 52 weeks
(0.92)‡76 (72 to 80)77 (73 to 81)Mental health index 8 weeks
75 (71 to 79)75 (70 to 80)Mental health index 52 weeks
(0.60)‡62 (58 to 67)64 (60 to 68)Vitality 8 weeks
59 (55 to 64)61 (56 to 66)Vitality 52 weeks
(0.34)‡63 (59 to 67)67 (63 to 71)General health perception 8 weeks
59 (55 to 63)62 (57 to 67)General health perception 52 weeks
Mean (95%CI) McGill Pain Questionnaire (0-78 points):
10 (8 to 12)11 (9 to 12)8 weeks
(0.70)‡10 (9 to 12)11 (9 to 13)52 weeks
Median (range) HADS depression score§:
3 (1-9)4 (0-9)Baseline
3 (0-9)3 (0-9)52 weeks
Median (range) HADS anxiety score§:
6 (2-12)7 (2-14)Baseline
6 (0-14)6 (1-12)52 weeks
(<0.001)§6 (8%)21 (29)No (%) reoperations
3 (50)10 (48)No (%) ZCQ success of reoperated patients
16 (18)21 (26)No (%) operated at two levels
(0.03)§18No of reoperations in patients operated at two levels
2.50 (0.06)48 (24 to 73)67 (45 to 83)% (95% CI) ZCQ success at 8 weeks
0.83 (0.83)53 (25 to 79)49 (29 to 69)% (95% CI) ZCQ success at 52 weeks
(<0.001)**43 (39 to 47)24 (22 to 26)Mean (95% CI) duration of operation (min)
(<0.001)**50-10010-50Blood loss (mL)—categorized¶
65Complications during hospital stay
††††3Spinous process fractures
(0.753)**1.89 (1.2)1.83 (0.9)Mean (SD) hospital stay
68 (86)54 (67)No (%) blinded to allocated treatment
HADS=Hospital Anxiety and Depression Scale; IPD=interspinous process device; ZCQ=Zurich Claudication Questionnaire.
*Outcomes were analyzed with generalized estimating equations (GEE).
†Odds ratio for better success rate when treated with IPD versus bony decompression, based on GEE.
‡Overall P value (based on GEE) of interaction between two groups based on continuous outcome scale (SF-36 and McGill).
§Score consists of sum score of 7 item (0-3 points per item) questionnaire ranging from 0 to 21 points; HADS-anxiety >8 is suspect for generalized anxiety disorder;
HADS-depression >8 is suspect for depression.
¶0-10 mL, 10-50 mL, 50-100 mL, 100-200 mL.
**P value with Fisher’s exact test and Pearson χ2.
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Table 3 (continued)
Odds ratio† (P value)DecompressionIPDOutcome
††Spinous process fractures were not registered as relevant complications in bony decompression group, so no comparison (or P value).
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Figures
Fig 1 Flow chart of enrollment and follow-up. IPD=interspinous process device
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Fig 2 Scores on Zurich Claudication Questionnaire (top), modified Roland Disability Questionnaire (middle), and visual
analogue scale (bottom) in two groups during follow-up. IPD=interspinous process device
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